Sylvant (Siltuximab) Market Report 2026

Sylvant (Siltuximab) Market Overview

• The Sylvant (Siltuximab) market growth in the historic period has been driven by increased diagnosis of multicentric castleman disease, improved awareness of cytokine-driven disorders • Market expansion is supported by increasing exploration of additional inflammatory indications, rising demand for precision immunotherapy solutions • Growth Driver: Rising Prevalence Of Multicentric Castleman Disease (MCD) Driving Growth Of The Market • Market Trend: Innovative Monoclonal Antibody Therapies Transform MCD Treatment • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Sylvant (Siltuximab) Market?

Sylvant (siltuximab) is a monoclonal antibody that targets and neutralizes interleukin-6 (IL-6), a cytokine involved in inflammation and immune responses. By inhibiting IL-6, it helps reduce inflammation and regulate immune activity, particularly in conditions such as multicentric castleman's disease (MCD). It is used to manage MCD symptoms, improve quality of life, and slow disease progression. The main types of indication for sylvant (siltuximab) are multicentric castleman disease (MCD), human immunodeficiency virus (HIV)-associated multicentric castleman disease (MCD), and non-Hodgkin lymphoma (NHL). Multicentric castleman disease (MCD) is a rare immune disorder causing lymphoid tissue overgrowth, and Sylvant (Siltuximab) treats it by targeting specific proteins to reduce inflammation and improve outcomes. It is used for several applications, such as injections, vials, lyophilized powder, solutions for infusion, and prefilled syringes, and is used by various end users, including hospitals, specialty clinics, ambulatory surgical centers (ASCs), and home care.

What Is The Sylvant (Siltuximab) Market Growth Forecast?

The growth in the forecast period can be attributed to increasing exploration of additional inflammatory indications, rising demand for precision immunotherapy solutions, advancements in biologic drug formulation, expansion of specialty clinic networks, improved global access to rare disease treatments. Major trends in the forecast period include increasing adoption of targeted il-6 inhibitor therapies, growing use in rare immunological disorders, expansion of monoclonal antibody treatment protocols, enhanced focus on inflammatory pathway modulation, improved patient outcome monitoring.

Global Sylvant (Siltuximab) Market Segmentation

1) By Indication: Multicentric Castleman Disease (MCD), Human Immunodeficiency Virus (HIV)-Associated Multicentric Castleman Disease (MCD), Non-Hodgkin Lymphoma (NHL) 2) By Application: Injections, Vials, Lyophilized Powder, Solution For Infusion, Prefilled Syringes 3) By End-User: Hospitals, Specialty Clinics, Ambulatory Surgical Centers (ASCs), Home Care

What Are The Drivers Of The Sylvant (Siltuximab) Market?

The increasing prevalence of multicentric castleman disease (MCD) is significantly driving the growth of the sylvant (siltuximab) market in the future. Multicentric castleman disease (MCD) is a rare condition involving the abnormal enlargement of lymph nodes and tissues, commonly linked to inflammation and immune system abnormalities. The rising cases of multicentric castleman disease (MCD) are attributed to factors such as improved diagnosis, greater awareness, and advancements in medical imaging. Sylvant (siltuximab) works by targeting and blocking interleukin-6 (IL-6), a cytokine that contributes to inflammation and disease progression in MCD. This inhibition helps reduce inflammation and control the abnormal growth of lymph nodes and tissues, offering an effective treatment for MCD patients. For instance, in February 2025, according to the Consult QD, a US-based medical news and education platform, the only FDA-approved treatment for this condition was used in just 22% of patients. This reveals a significant unmet treatment need, considering this is the only FDA-approved drug for iMCD in the U.S. Therefore, increasing prevalence of multicentric castleman disease (MCD) is driving the growth of the sylvant (siltuximab) industry. The shifting focus toward precision medicine is expected to propel the growth of the sylvant (siltuximab) market going forward. Precision medicine is a healthcare approach that customizes treatments based on a person's unique genetic makeup, environment, and lifestyle. The demand for precision medicine is rising due to advancements in genetic research, increasing prevalence of personalized healthcare, and growing adoption of targeted therapies. Sylvant (siltuximab) targets and inhibits interleukin-6 (IL-6), a cytokine involved in inflammation and disease progression. By specifically addressing elevated IL-6 levels in patients with multicentric castleman disease (MCD), it offers a more personalized and more effective treatment compared to standard therapies. For instance, in February 2024, according to the Personalized Medicine Coalition, a US-based hospital and healthcare organization, in 2023, the FDA approved 16 new personalized treatments for rare disease patients, up from six in 2022. Therefore, the shifting focus toward precision medicine is driving the growth of the sylvant (siltuximab) industry.

Key Players In The Global Sylvant (Siltuximab) Market

Major companies operating in the sylvant (siltuximab) market are Recordati Rare Diseases Inc.

Global Sylvant (Siltuximab) Market Trends and Insights

Major companies operating in the Sylvant (Siltuximab) market are focusing on developing innovative solutions, such as monoclonal antibody therapies, to meet the rising demand for targeted treatment options for multicentric Castleman disease (MCD). Monoclonal antibody therapies are designed to specifically bind to disease-associated proteins, helping modulate immune responses and improve patient outcomes compared to conventional treatments. For instance, in September 2024, the European Commission, a Belgium-based executive body of the European Union responsible for proposing and enforcing EU policies and legislation, approved SYLVANT (siltuximab) as a treatment for MCD. SYLVANT is a monoclonal antibody that binds to interleukin-6 (IL-6), inhibiting its activity, which helps reduce inflammation and disease symptoms. This therapy provides a targeted, non-chemotherapy option for patients with MCD.

Regional Insights

North America was the largest region in the sylvant (siltuximab) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

What Defines the Sylvant (Siltuximab) Market?

The sylvant (siltuximab) market consists of sales of oral dosage forms, compounded solutions, and intravenous (IV) infusion bags. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Sylvant (Siltuximab) Market Report 2026?

The sylvant (siltuximab) market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the sylvant (siltuximab) industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.